919 Clinically meaningful improvement in disease-related symptoms by gefitinib (‘Iressa’, ZD1839) in patients with advanced non-small-cell lung cancer: relationship between lung cancer subscale scores and radiographic response and survival

J.-Y.Douillard; D.Cella; R.B.Natale; T.J.Lynch; C.Lee; D.Carbone; A.Kay; M.Wolf; A.Heyes; J.Ward

首页> 外文期刊>European Journal of Cancer Supplements >919 Clinically meaningful improvement in disease-related symptoms by gefitinib (‘Iressa’, ZD1839) in patients with advanced non-small-cell lung cancer: relationship between lung cancer subscale scores and radiographic response and survival

【24h】

919 Clinically meaningful improvement in disease-related symptoms by gefitinib (‘Iressa’, ZD1839) in patients with advanced non-small-cell lung cancer: relationship between lung cancer subscale scores and radiographic response and survival

机译：919吉非替尼（Iressa，ZD1839）对晚期非小细胞肺癌患者的疾病相关症状的临床意义改善：肺癌子量表评分与影像学反应和生存之间的关系

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2003年第5期|共2页
作者
J.-Y.Douillard; D.Cella; R.B.Natale; T.J.Lynch; C.Lee; D.Carbone; A.Kay; M.Wolf; A.Heyes; J.Ward;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 825 Statistical analysis of survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib (‘Iressa’, ZD1839) in an expanded access program (EAP): preliminary results [J] . M.Wolf, D.Farina-Sisofo, J.Grous, European Journal of Cancer Supplements . 2003,第5期

机译：825在扩展访问计划（EAP）中，接受吉非替尼（“ Iressa”，ZD1839）治疗的晚期非小细胞肺癌（NSCLC）患者生存率的统计分析：初步结果
2. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). [J] . Thatcher N, Chang A, Parikh P, The Lancet . 2005,第9496期

机译：吉非替尼联合先前治疗的难治性晚期非小细胞肺癌患者的最佳支持治疗：一项随机，安慰剂对照，多中心研究的结果（肺癌Iressa生存率评估）。
3. Clinically meaningful response to the EGFR tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in non small cell lung cancer. [J] . Gelibter A, Ceribelli A, Milella M, Journal of experimental & clinical cancer research : . 2003,第3期

机译：在非小细胞肺癌中对EGFR酪氨酸激酶抑制剂吉非替尼（'Iressa'，ZD1839）的临床有意义的反应。
4. The impact of the type of resection on survival in patients with N1 non-small-cell lung cancers [C] . Umit Aydogmus, Levent Cansever, Yasar Sonmezoglu, 21st international conference on screening for lung cancer . 2009

机译：切除类型对N1非小细胞肺癌患者生存的影响
5. Symptoms Leading to Nutritional Risk in Advanced Non-Small Cell Lung Cancer Patients: The Importance of Nutritional Screening in the Advanced Lung Cancer Population [D] . Swinton, Nelda. 2009

机译：导致晚期非小细胞肺癌患者营养风险的症状：在晚期肺癌人群中进行营养筛查的重要性
6. Evaluation of safety and efficacy of gefitinib (iressa zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme [O] . Xin-Lin Mu, Long-Yun Li, Xiao-Tong Zhang, 2004

机译：吉非替尼（ iressazd1839）作为单药治疗在一系列中国晚期非小细胞肺癌患者中的安全性和疗效评估：同情使用计划的经验
7. Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme [O] . 2004

机译：吉非替尼（“ iressa”，zd1839）作为单药治疗在一系列中国晚期非小细胞肺癌患者中的安全性和有效性评估：同情使用计划的经验

919 Clinically meaningful improvement in disease-related symptoms by gefitinib (‘Iressa’, ZD1839) in patients with advanced non-small-cell lung cancer: relationship between lung cancer subscale scores and radiographic response and survival

著录项

相似文献

相关主题

期刊订阅